Keppra and Encephalitis viral - a phase IV clinical study of FDA data

Summary:

Encephalitis viral is reported as a side effect among people who take Keppra (levetiracetam), especially for people who are male, 2-9 old, have been taking the drug for < 1 month also take Dilantin, and have Anaplastic astrocytoma.

The phase IV clinical study analyzes which people have Encephalitis viral when taking Keppra. It is created by eHealthMe based on reports of 70,297 people who have side effects when taking Keppra from the FDA, and is updated regularly.

What is Keppra?

Keppra has active ingredients of levetiracetam. It is often used in epilepsy. eHealthMe is studying from 73,504 Keppra users. Check the latest studies of Keppra.

What is Encephalitis viral?

Encephalitis viral (inflammation of the brain due to viral infection) is found to be associated with 147 drugs and 307 conditions by eHealthMe. Check the latest studies of Encephalitis viral.

On Aug, 13, 2026

70,297 people reported to have side effects when taking Keppra.
Among them, 20 people (0.03%) have Encephalitis viral.

Among these 20 people:

How long have people been on Keppra when they have Encephalitis viral? *

What is the gender of people who have Encephalitis viral when taking Keppra? *

female: 31.58 %
male: 68.42 %

What is the age of people who have Encephalitis viral when taking Keppra? *

What are other drugs people take besides Keppra? *

What are other side effects people have besides Encephalitis viral? *

Confusional State: 3 people, 15.00%
Mental Status Changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation): 2 people, 10.00%
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets): 2 people, 10.00%
Partial Seizures (seizures which affect only a part of the brain at onset): 2 people, 10.00%
Cognitive Disorder (mental health disorders affects learning, memory, perception, and problem solving): 2 people, 10.00%
Nosebleed (bleeding from nose): 2 people, 10.00%
Cerebellar Atrophy (degeneration of the section of the brain responsible for balance, voluntary muscle movements): 2 people, 10.00%
Respiratory Syncytial Virus Infection (viral disease of respiratory system): 2 people, 10.00%
Speech Disorder: 2 people, 10.00%
Acute Cerebellar Ataxia (disorder of the nervous system-sudden onset of a disturbance in coordination): 2 people, 10.00%

What are the existing conditions these people have? *

Anaplastic Astrocytoma (tumour of the glial (supportive) tissue of the brain): 3 people, 15.00%
Seizure Cluster (small group of seizure): 2 people, 10.00%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 10.00%
Febrile Convulsion (a convulsion associated with a significant rise in body temperature): 2 people, 10.00%
Status Epilepticus (a life-threatening condition in which the brain is in a state of persistent seizure): 1 person, 5.00%
Primary Myelofibrosis (primary disorder of the bone marrow): 1 person, 5.00%
Partial Seizures (seizures which affect only a part of the brain at onset): 1 person, 5.00%
Lung Cancer - Non-Small Cell (lung cancer): 1 person, 5.00%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 5.00%
Growth Hormone Deficiency: 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Keppra and have Encephalitis viral?

- Check whether Encephalitis viral is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Keppra:

Keppra (73,504 reports)

Browse all side effects of Keppra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Encephalitis viral:

Encephalitis viral (147 drugs)

Browse all the conditions that are associated with Encephalitis viral:

Encephalitis viral (307 conditions)

Related publications that referenced our studies

Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
Spengler DC, Montouris GD, Hohler AD, "Levetiracetam as a possible contributor to acute kidney injury", Clinical therapeutics, 2014 Aug .
Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM, "Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report", Pancreas, 2013 Jan .
Schattner A, Al-Bewerat A, "Levetiracetam (Keppra), urinary retention and literature search", A fatty cause of renal failure; what is your diagnosis?, 2016 Oct .
Spengler DC, Montouris GD, Hohler AD, "Levetiracetam as a possible contributor to acute kidney injury", Clinical therapeutics, 2014 Aug .
Almeida DM, Jean MR, Chystsiakova A, Monahan E, Oliveira SB, Monteiro IM, "Levetiracetam-associated acute pancreatitis in an adolescent with autism: a case report", Pancreas, 2013 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on levetiracetam (the active ingredients of Keppra) and Keppra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.